MedTrace Logo

Study Evaluating Safety & Immunogenicity of rLP2086 Vaccine in Adolescents

NCT00387725 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 127

Last updated 2014-11-21

Study results available
· View outcomes & findings →

Summary

Study to evaluate the safety of an investigational meningitis vaccine and the immune response to it in adolescents

Conditions

  • Healthy

Interventions

BIOLOGICAL

rLP2086

Vaccine administered at 0, 1, and 6 months

BIOLOGICAL

rLP2086

Vaccine administered at 0, 1, and 6 months

BIOLOGICAL

rLP2086

Vaccine administered at 0, 1, and 6 months

BIOLOGICAL

rLP2086

Vaccine administered at 0, 1, and 6 months

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
8 Years
Max Age
14 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-11-30
Primary Completion
2008-01-31
Completion
2008-02-29

Countries

  • Australia

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00387725 on ClinicalTrials.gov